Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
85.40
+0.47 (0.55%)
At close: Apr 2, 2026, 4:00 PM EDT
87.10
+1.70 (1.99%)
After-hours: Apr 2, 2026, 6:44 PM EDT
Kymera Therapeutics Revenue
In the year 2025, Kymera Therapeutics had annual revenue of $39.21M, down -16.70%. Kymera Therapeutics had revenue of $2.87M in the quarter ending December 31, 2025, a decrease of -61.18%.
Revenue (ttm)
$39.21M
Revenue Growth
-16.70%
P/S Ratio
177.81
Revenue / Employee
$164,752
Employees
238
Market Cap
6.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.21M | -7.86M | -16.70% |
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Krystal Biotech | 389.13M |
| Rhythm Pharmaceuticals | 189.76M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
| Protagonist Therapeutics | 46.02M |
| Arcellx | 22.29M |
| Centessa Pharmaceuticals | 15.00M |
KYMR News
- 6 days ago - Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 22 days ago - Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 24 days ago - Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase - Seeking Alpha
- 5 weeks ago - Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewsWire